Freeman Kevin D's Form 4/A amendment
AmendedGalectin Therapeutics Inc (GALT) · filed Jan 19, 2022
- Accession no.
- 0001133416-22-000010
- Filed
- Jan 19, 2022
- Trade date
- Jan 19, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Jan 19, 2022
This filing lists 1 non-derivative transaction. Open-market purchases total $9.80K. It was filed on the trade date.
This amendment replaces 0001133416-22-000008 (filed Jan 19, 2022).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Freeman Kevin DCIK 0001522478 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 19, 2022 | Common Stock | PPurchaseAcquired | +5,000 | $1.96 | +$9,800 | 55,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.